11,175 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by Conway Capital Management Inc.

Conway Capital Management Inc. bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the third quarter, HoldingsChannel.com reports. The firm bought 11,175 shares of the medical research company’s stock, valued at approximately $737,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Wellington Management Group LLP grew its holdings in shares of Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares during the period. State Street Corp grew its stake in shares of Edwards Lifesciences by 1.0% during the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock valued at $1,733,270,000 after purchasing an additional 256,538 shares during the period. Bank of New York Mellon Corp increased its position in shares of Edwards Lifesciences by 4.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after purchasing an additional 809,605 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of Edwards Lifesciences by 9.8% in the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after purchasing an additional 806,705 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Edwards Lifesciences by 1.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,005,789 shares of the medical research company’s stock worth $396,322,000 after buying an additional 61,275 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research reports. Canaccord Genuity Group upped their target price on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a report on Thursday, December 5th. Barclays raised their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Morgan Stanley reissued an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a report on Friday, October 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Finally, JPMorgan Chase & Co. boosted their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Seventeen investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $78.35.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 40,000 shares of company stock worth $2,657,000 in the last three months. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $70.91 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The business has a 50 day simple moving average of $68.75 and a two-hundred day simple moving average of $74.29. The stock has a market capitalization of $41.82 billion, a PE ratio of 10.23, a P/E/G ratio of 3.52 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the firm posted $0.59 earnings per share. On average, research analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.